Larkin Cristina 4
4 · Spero Therapeutics, Inc. · Filed Jul 6, 2018
Insider Transaction Report
Form 4
Larkin Cristina
Chief Operating Officer
Transactions
- Exercise/Conversion
Common Stock
2018-07-05$5.90/sh+4,000$23,600→ 5,500 total - Sale
Common Stock
2018-07-05$17.50/sh−4,000$70,000→ 1,500 total - Exercise/Conversion
Stock Option (Right to Buy)
2018-07-05−4,000→ 20,434 totalExercise: $5.90Exp: 2027-07-05→ Common Stock (4,000 underlying)
Footnotes (2)
- [F1]The option exercises and related sales reported in this Form 4 were made pursuant to a Rule 10b5-1 trading plan previously entered into by the Reporting Person in December 2017.
- [F2]The shares underlying this option vested as to 25% on March 7, 2017, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.